玻璃体腔注射雷珠单抗治疗糖尿病性黄斑水肿临床效果分析  

Clinical effect analysis of intravitreal injection of ranibizumab in the treatment of diabetic macular edema

作　　者：刘璐[1] 陈明[1] 柴广睿[1] 

机构地区：[1]中国医科大学附属盛京医院眼科,沈阳110004

出　　处：《中国医学前沿杂志（电子版）》2016年第4期85-87,共3页Chinese Journal of the Frontiers of Medical Science(Electronic Version)

摘　　要：目的研究玻璃体腔注射雷珠单抗对糖尿病性黄斑水肿(diabetic macular edema,DME)的临床治疗效果。方法选取2015年1月至2015年8月于本院眼科确诊的DME患者36例(36眼)为研究对象,行玻璃体腔注射雷珠单抗治疗。观察并比较治疗前后患者最佳矫正视力、黄斑中心凹视网膜厚度及黄斑中心凹下脉络膜厚度的变化情况。结果所有患者治疗后1个月平均最佳矫正视力显著优于治疗前(P<0.05),且黄斑中心凹视网膜厚度、黄斑中心凹下脉络膜厚度均显著下降(P<0.05)。结论玻璃体腔注射雷珠单抗治疗DME,临床效果显著,且黄斑中心凹视网膜厚度可作为评估预后的指标之一。Objective To observe the clinical effect of intravitreal injection of ranibizumab in the treatment of diabetic macular edama（DME）,Method A total of 36 patients（36 eyes） diagnosed DME from January2015 to August 2015 in our hospital were selected as the research objects,and received intravitreal injection of ranibizumab,Dectected and compared the best corrected visual acuity,foveal retinal thinckness,subfoveal choroidal thinckness hefore and after treatment.Result 1 month after treatment,the best corrected visual acuity had obviously increased（P〈0.05）,and the foveal retinal thickness as well as subfoveal choroidal thinckness had significantly decreased（P〈0,05）.Conclusion Intravitreal injection of ranibizumab in the treatment of DME can improve the best corrected visual auity of DME patients,and can relieve macular edema without series complications.The thickness of foveal retinal thickness may be a clinical index to evaluate the prognosis.

关 键 词：雷珠单抗 糖尿病性黄斑水肿 视网膜病变 

分 类 号：R587.2[医药卫生—内分泌]